Pulse Biosciences, Inc.

NasdaqCM PLSE

Pulse Biosciences, Inc. Net Income Margin for the Trailing 12 Months (TTM) ending September 30, 2024: -2,651.32%

Pulse Biosciences, Inc. Net Income Margin is -2,651.32% for the Trailing 12 Months (TTM) ending September 30, 2024. Net Income Ratio, also known as the profit margin, is the ratio of net income to net sales, showing the percentage of revenue that remains as profit after all expenses are deducted.

Pulse Biosciences, Inc. Net Income Margin for the Trailing 12 Months (TTM) ending September 30, 2022 was -4,167.42%, a 61.41% change year over year.
Pulse Biosciences, Inc. Net Income Margin for the Trailing 12 Months (TTM) ending September 30, 2021 was -10,800.35%.

Key data

Date	Net Income Margin	EBITDA Margin	EBIT Margin	EBITDA

NasdaqCM: PLSE

Pulse Biosciences, Inc.

CEO	Mr. Robert W. Duggan
IPO Date	May 18, 2016
Location	United States
Headquarters	3957 Point Eden Way
Employees	56
Sector	Health Care
Industries Biotechnology Energy Storage & Batteries Pharmaceuticals

Description

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.

Key trends

Past 5 years